素基因相关的类单克隆抗体治疗新出现的每日持续性头痛
Sanjay Cheema1,2, Khadija Rerhou Rantell3, Rachel Pickering2
1Headache and Facial Pain Group, University College London (UCL) Queen Square Institute of Neurology, London, UK.
The journal of headache and pain
|July 28, 2025
概括
与素基因相关的单克隆抗体 (CGRP mAbs) 在新发每日持续性头痛 (NDPH) 中表现出有限的疗效,这表明它与慢性偏头痛不同. 为了有效的NDPH治疗,需要进一步的研究.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 新的每日持续性头痛 (NDPH) 是一种罕见的疾病,其表型与慢性偏头痛 (CM) 相似,但从发病开始每天都会出现.
- 与素基因相关的单克隆抗体 (CGRP mAbs) 对CM有效,但其对NDPH的有效性尚不清楚.
研究的目的:
- 评估CGRP mAbs在NDPH中的疗效,耐受性和安全性.
- 为了比较CGRP mAbs在NDPH和CM中的影响.
主要方法:
- 一项对48名NDPH患者的观察性研究,每日CM患者为101,非每日CM患者为68,接受CGRP mAbs.治疗.
- 倾向性得分匹配用于平衡基线特征.
- 主要终点:12周每月中度至重度头痛日数 (MSHD) 的减少.
主要成果:
- 23%的NDPH患者实现了≥30%的MSHD减少,而每日CM的46%和非每日CM的84%相比.
- 11%的NDPH患者每月头痛日有所改善,54%的人报告主观改善.
- 不良事件在各组中都轻微且相似,影响了近50%的患者.
结论:
- 在治疗不耐药的NDPH患者中,CGRP mAbs在约23%的患者中是有效的,但比CM有效率要低.
- 不应将NDPH视为同等于CM,强调需要新的治疗策略.
- 进一步研究NDPH的新治疗方案是有必要的,因为它具有很高的残疾.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
259
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
259
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
262
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
262
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
235
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
235


